NCT00794807View on ClinicalTrials.gov

Safety and Tolerability of Repeat Courses of IM Alefacept

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Chronic Plaque Psoriasis
Interventions
DRUG

Alefacept

Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.

Trial Locations (1)

10117

Psoriasis Study center, The interdisciplinary group of Molecular Immunopathology, Berlin

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT00794807 - Safety and Tolerability of Repeat Courses of IM Alefacept | Biotech Hunter | Biotech Hunter